

## PROLACTINOMA MANAGEMENT

**Mark E. Molitch, M.D.** Division of Endocrinology, Metabolism and Molecular Medicine, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL 60611. [molitch@northwestern.edu](mailto:molitch@northwestern.edu)

**Juliana Drummond**, Department of Internal Medicine of the Federal University of Minas Gerais, Belo Horizonte/Minas Gerais, 30130-100, Brazil, [jubeaudette@hotmail.com](mailto:jubeaudette@hotmail.com)

**Márta Korbonits, MD, PhD, DSc, FRCP**, Centre for Endocrinology, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, UK, [m.korbonits@qmul.ac.uk](mailto:m.korbonits@qmul.ac.uk)

**Updated January 4, 2022**

### ABSTRACT

Prolactinomas comprise nearly 40% of all pituitary tumors. Patients with prolactinomas usually come to medical attention as a result of symptoms caused by elevated prolactin levels, such as hypogonadism, menstrual irregularities, infertility or galactorrhea, or due to mass effects. Sometimes these patients can present as an emergency, either due to a visual field defect or loss of vision, or due to acute severe headache caused by pituitary apoplexy associated with hypopituitarism. Most patients with hyperprolactinemia do not have prolactinomas. A number of physiological conditions as well as several medications can also cause prolactin elevations; in these instances, prolactin levels are usually < 150 ng/mL (3000 mIU/L). Hyperprolactinemia can also result from reduced dopamine reaching the

lactotrophs due to stalk compression. Furthermore, when evaluating patients with only modestly elevated prolactin levels and large macroadenomas, one should be aware of the “hook effect”, caused by saturation of antibodies of a two-site immunoassay by very high prolactin levels. A dopamine agonist is the treatment of choice in the vast majority of cases. Dopamine agonists can normalize prolactin levels, restore the function of the gonadal axis, stop galactorrhea, and significantly decrease tumor size in the vast majority of the patients, with cabergoline generally being more efficacious and better tolerated than bromocriptine. Indeed, cabergoline is first-line therapy even in patients with visual field defects as long as visual acuity is not threatened by rapid progression or recent tumor hemorrhage. Cerebrospinal fluid leakage could be a complication of dopamine agonists if they cause rapid tumor

shrinkage and there is disruption of the sellar floor by the tumor. Transsphenoidal surgery is an alternative treatment in cases of dopamine agonist resistance or intolerance. Radiation therapy is reserved for those rare patients with macroadenomas not responding to either medical or surgical treatment. Symptomatic growth during pregnancy may occurs in about 20-25% of macroprolactinomas, and therefore visual field testing is indicated each trimester in such patients. MRI scans (without gadolinium) are done in those patients who develop visual field defects or severe headaches when a therapeutic intervention is contemplated.

## CLINICAL RECOGNITION

Patients with prolactinomas come to clinical recognition because of the effects of elevated

prolactin levels or tumor mass effects. The most typical symptoms of hyperprolactinemia in premenopausal women are oligo/amenorrhea (approximately 90%) and galactorrhea (approximately 80%) (1). Non-puerperal galactorrhea may occur in 5-10% of normally menstruating, normoprolactinemic women, and therefore is suggestive, but not definitive, of hyperprolactinemia. However, when oligo/amenorrhea is associated with galactorrhea, about 75% of women will be found to have hyperprolactinemia. Galactorrhea is reported in ~10% of cases in men with prolactinomas and is virtually pathognomonic of a prolactinoma. Hyperprolactinemia inhibits the pulsatile secretion of gonadotropin releasing hormone via interfering with hypothalamic kisspeptin-secreting cells via the prolactin receptor, and may involve an opioid link (2).

**Table 1. Etiology of Hyperprolactinemia**

### **Pituitary Disease**

Prolactinomas  
Acromegaly  
Clinically nonfunctioning pituitary adenomas  
Empty Sella syndrome  
Hypophysitis

### **Hypothalamic Disease**

Craniopharyngiomas  
Meningiomas  
Germinomas  
Other tumors  
Sarcoidosis  
Langerhans cell histiocytosis  
Neuroaxis irradiation  
Vascular  
Pituitary Stalk Section

### **Medications**

Phenothiazines  
Butyrophenones  
Atypical Antipsychotics  
Tricyclic Antidepressants  
Serotonin Reuptake Inhibitors  
Reserpine

Methyldopa
Verapamil
Metoclopramide
<b>Neurogenic</b>
Chest wall/Breast lesions
Spinal Cord lesions
<b>Other</b>
Pregnancy
Breast-feeding
Hypothyroidism
Renal Insufficiency
Adrenal Insufficiency
Ectopic prolactin production
Familial hyperprolactinemia (mutated prolactin receptor)
Untreated phenylketonuria
Macroprolactinoma
<b>Idiopathic</b>

## **PATHOPHYSIOLOGY**

Prolactinomas comprise 25 to 40% of all pituitary adenomas (3). The vast majority of prolactinomas are sporadic. Familial cases of prolactinomas are very rare and occur usually in association with Multiple Endocrine Neoplasia type 1 or the Familial Isolated Pituitary Adenoma syndrome. Genetic testing for young-onset macroprolactinomas should include the *MEN1* and *AIP* genes and more rarely due to *MEN4*, *MEN5* or associated with paragangliomas (4-6). Similar to other types of pituitary adenomas, prolactinomas arise from a single transformed cell (lactotroph) with monoclonal proliferation. A number of candidate somatic genetic alterations involved in the genesis and progression of prolactinomas have been looked for but, except for a recently described splicing factor 3 subunit B1 (*SF3B1*) gene somatic mutation in approximately 20% of over 200 surgically resected prolactinomas (7) (this study is awaiting independent replication), no other specific mutations have been found that account for more than a handful of cases at this point.

## **DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS**

The majority of patients with hyperprolactinemia do not actually have prolactinomas (Table 1) (8,9). Drug-induced hyperprolactinemia is the most common, and a number of physiological conditions, including stress (psychological or associated with acute illness), exercise and sleep can also cause prolactin elevation. The hyperprolactinemia caused by drugs and other non-prolactinoma causes is usually <150 ng/mL (3000 mIU/L). Many medications block dopamine release or action, the most common being antipsychotic medications, verapamil, and metoclopramide. The best way to determine whether hyperprolactinemia is drug-induced or not is to discontinue the drug or switch to another drug in a similar class that is not known to cause hyperprolactinemia and see if the prolactin levels return to normal within 72 hours. The best example is the partial dopamine receptor agonist aripiprazole, which has been shown to be effective in attenuating antipsychotic medication-induced hyperprolactinemia (10).

A variety of suprasellar lesions cause hyperprolactinemia because of compression of the hypothalamus or pituitary stalk with decreased dopamine reaching the lactotrophs. These can be mass lesions, such as craniopharyngiomas or meningiomas, or infiltrative disease, such as sarcoidosis and Langerhans cell histiocytosis. The high estrogen levels of pregnancy cause lactotroph hyperplasia and hyperprolactinemia, so pregnancy must always be excluded. The estrogen levels produced by oral contraceptives or post-menopausal hormonal replacement therapy generally do not cause hyperprolactinemia. Hypothyroidism and renal failure (serum creatinine >2 mg/dL (176 µmol/L)) can also cause hyperprolactinemia (11). Thus, the initial laboratory evaluation involves repeat measurement of prolactin, a TSH, a serum creatinine, and a pregnancy test. Unless there is very good evidence for these conditions or drug-induced hyperprolactinemia, even patients with mild hyperprolactinemia should be evaluated with radiological methods, preferably MRI, to distinguish among idiopathic hyperprolactinemia, microprolactinomas, and large mass lesions. Measurement of IGF-1 is recommended for patients presenting with hyperprolactinemia and pituitary adenomas (11,12) as prolactin may be elevated in up to 50% of patients with GH-secreting tumors (13).

Special caution is needed when two-site ('sandwich') prolactin assays are used, as patients with large prolactinomas and very high prolactin levels may appear to have prolactin levels that are normal or only modestly elevated, thus mimicking a large, nonfunctioning adenoma. This "hook effect" is due to saturation of the assay antibodies and prolactin


levels should always be remeasured at 1:10 or 1:100 dilution in patients with large macroadenomas and normal to modestly elevated prolactin levels (14).

Sometimes prolactin levels are elevated due to increased amounts of macroprolactin. Macroprolactin consists of high molecular weight prolactin variants that are either aggregates with immunoglobulins or dimers, and have diminished biologic potency. Macroprolactin can be detected in the serum by precipitating the complex with polyethylene glycol. In normal individuals, macroprolactin comprises < 30% of circulating prolactin; therefore, if after precipitation with polyethylene glycol the prolactin levels in the supernatant are > 70% of the upper limit of normal for the assay, the patient can be assumed to have true hyperprolactinemia and not an elevation due simply to macroprolactin. Macroprolactinoma has usually been found in patients with equivocal symptoms and not those typically due to hyperprolactinemia. A lack of recognition of the presence of macroprolactin can lead to unnecessary laboratory investigations, imaging, and pharmacologic or surgical treatment.

When no pituitary lesions are seen by radiological studies and other known causes have been excluded, the diagnosis of idiopathic hyperprolactinemia is made; in long term follow-up, although prolactin levels may rise to over 50% of the baseline in 10-15% of the patients, only about 10% develop detectable microadenomas, one-third resolve their hyperprolactinemia without specific intervention and prolactin levels remain stable in most patients (15).

## TREATMENT

# Patient with macroadenoma



**Figure 1. Serum prolactin measurement is required in all patients presenting with hypothalamic-pituitary lesions before surgery (Figure courtesy of D. Korbonits)**

Not all patients require treatment. If a patient with a microadenoma or idiopathic hyperprolactinemia presents with non-bothersome galactorrhea and has normal estrogen/testosterone levels they can simply be followed with periodic prolactin levels. Similar patients who may have amenorrhea but are not interested in fertility may be treated with estrogen replacement. However, for most symptomatic patients, a dopamine agonist is the therapy of choice. Dopamine agonists normalize prolactin levels, correct amenorrhea-galactorrhea, and decrease tumor size by more than 50% in 80-90% of patients, with cabergoline generally being more efficacious and better tolerated than bromocriptine (11,16). Thus, defining whether a pituitary tumor is a prolactinoma is crucial for optimal patient management since it is reasonable to use cabergoline as first-line therapy even in patients with visual field defects as long as visual acuity is not threatened by rapid progression or recent tumor hemorrhage (Figure 1). Starting dose in

these cases could be higher than usual, some colleagues suggest 0.5 mg/day with close in-patient monitoring. Vision often starts to improve within days after the initiation of dopamine agonist therapy.

In non-emergent situations cabergoline is usually initiated at 0.25-0.5 mg/week (taken initially carefully with meal just before bedtime, to reduce nausea and improve compliance), whereas the initial dose of bromocriptine is 1.25 mg/day. About 40-50% of patients, whose prolactin levels normalize and tumors shrink to the point of non-visualization, can be tapered off cabergoline without tumor re-expansion. Factors associated with greater risk of recurrence are the presence of pituitary deficits at diagnosis and higher prolactin levels, both at diagnosis and before withdrawal (17).

A rare but significant side-effect of dopamine agonist treatment is cerebrospinal fluid leakage (CSF) leak,

---

due to the rapid shrinkage of a large prolactinoma allowing CSF to escape if significant damage is present at the fossa floor (18). Patients should be advised to present if clear fluid appears and this should be tested for beta-2 transferrin (12,19). If positive, patients need urgent neurosurgical input with transnasal surgery or lumbar drain being possible approaches in addition to antibiotic therapy, if necessary (18,20). Discontinuing dopamine agonist therapy is not usually recommended as it may cause recurrence of the tumor (21). Dopamine agonist therapy has been implicated as a precipitating factor for pituitary apoplexy in patients with prolactinomas (22,23). Nonetheless, prolactinomas are, by themselves, more prone to bleeding, and the reported prevalence of pituitary apoplexy in macroprolactinomas treated with dopamine agonists, ranging from 1% to 6%, is not significantly different from the rate recorded in untreated prolactinomas (24). Further precipitating factors which have been associated with pituitary apoplexy are cerebral angiography, surgical procedures, head trauma, dynamic tests, anticoagulation therapy and pregnancy (25,26).

A well-described side-effects of dopamine agonists include psychiatric complications, such as depression, anxiety, insomnia, hallucinations, mania. More recently impulse control disorders have also been described in pituitary adenoma patients (12,27-29). The underlying mechanism is related to an interaction between the dopamine agonists and the D3 receptor in the mesolimbic system (30). Impulse control disorders can manifest as hypersexualism, gambling, compulsive eating, compulsive shopping, and “punding” (compulsive performance of and fascination with repetitive mechanical tasks, for example assembling and disassembling household objects or collecting or sorting various items) (29), with hypersexualism and gambling being the most commonly observed in pituitary patients. Hypersexualism has also been described in teenage children (31). Although impulse control disorders are

infrequent, they have the potential to cause devastating consequences on patients’ life and clinicians should be sensitive to these potential side-effects discussing it with the patient at the start of treatment and during long-term follow-up (29). Discontinuation of the dopamine agonists usually reverses these side-effects (28).

In some cases, prolactinomas appear to be resistant to a dopamine agonist, but it is important to ensure compliance and to be certain that the underlying lesion is a prolactinoma and not some other cause of hyperprolactinemia. About 50% of patients resistant to bromocriptine will then respond to cabergoline. Most patients resistant to standard doses of cabergoline respond to larger doses (32). T2-weighted MRI intensity may aid as a tool for predicting response to dopamine agonists. Prolactinomas showing T2-weighted MRI signal heterogeneity are more common in males, are usually larger, more secreting and may show poorer hormonal response to dopamine agonists as compared with homogeneous prolactinomas (33). In females, T2-weighted MRI tumor hypointensity has been associated with higher prolactin levels at diagnosis and dopamine agonists resistance (34). Previous reports in patients taking cabergoline for Parkinson’s disease have shown that doses >3 mg/day may be associated with cardiac valvular abnormalities. Whether similar valvular changes occur in patients receiving low-dose cabergoline for treatment of hyperprolactinemia is still debatable, common practice has been to perform periodic echocardiograms every 12 to 24 months in patients taking >2 mg/week (35). However, a clinically significant association between low-dose cabergoline and cardiac valvulopathy is not supported by a large multicenter follow-up study (36). More recently, a meta-analysis of case-control studies evaluating patients who had received ≥6 months cabergoline treatment for hyperprolactinemia reported an increased risk of tricuspid regurgitation in the cabergoline-treated patients compared to controls



(37). Nevertheless, these results were mainly influenced by the results from a single center (38) and in the majority of the reviewed studies there were no cases of moderate-severe tricuspid regurgitation in either group. Furthermore, neither cumulative dose nor treatment duration was associated with an increased risk of moderate-severe valve lesions (37) and none of these lesions were found as a result of cardiac symptoms. According to the recent cross-sectional CATCH study conducted among 174 community-based adults (mean age of 49 years) receiving dopamine agonists for >12 months for hyperprolactinemia and no cardiac-related symptoms, cabergoline use and greater cumulative cabergoline exposure (>115 mg) were associated with a higher prevalence of valvular regurgitation, i.e.,  $\geq 2$  valves with grade 2+ regurgitation, compared with bromocriptine (39). Therefore, these data would suggest that some degree of monitoring is appropriate, although at substantially reduced frequency than currently recommended (40). Indeed, some experts suggest echocardiographic monitoring should be reserved for those patients with an audible murmur, those treated for more than 5 years at a dose of more than 3 mg per week, or those who maintain cabergoline treatment after the age of 50 years (41).

An alternative approach is transsphenoidal surgery, which has initial remission rates of approximately 75% for microprolactinomas and 40% for macroadenomas, and long-term recurrence rates of nearly 20% and 35%, respectively, when performed by expert neurosurgeons (42). Transsphenoidal surgery is usually reserved for patients with resistance or intolerance to dopamine agonists; macroprolactinomas with chiasmal compression and visual deficits without rapid improvement on medical treatment, or with acute tumor complications, such as symptomatic apoplexy or cerebrospinal fluid leakage (12). Complications of hypopituitarism, infections and bleeding are minimal, but increase proportionately with tumor size. Craniotomy for large tumors is rarely

curative and is fraught with much higher complication rates. Radiation therapy is reserved for those patients with macroadenomas not responding to either medical or surgical treatment. Radiation therapy in all forms is associated with a high rate of hypopituitarism that develops gradually over many years. Temozolomide, an orally-active alkylating chemotherapeutic agent, is reserved for the treatment of aggressive prolactinomas refractory to other treatment modalities (43).

## **FOLLOW-UP**

The goals of treatment are to normalize prolactin levels or at least bring them to levels at which gonadal/reproductive/sexual function is normalized and to decrease tumor size. As noted, according to different series, nearly 80% of patients treated with dopamine agonists will reach these prolactin goals and achieve significant tumor size reduction (44-46). Once prolactin levels have reached normal or near-normal level, they can just be monitored every 3-6 months for the first year and then every 6-12 months thereafter. Macroadenoma tumor size can be monitored by serial MRI scans and once maximal size reduction has been documented, further scans may not be necessary as long as prolactin levels are being monitored. Whether a second MRI scan is necessary in patient with microadenomas is debatable if prolactin levels are regularly monitored. It is extremely rare for a tumor to increase in size without there being a significant increase in prolactin levels. Visual field testing should be repeated until they normalize or remain stable and then do not need to be repeated.

## **PREGNANCY**

Dopamine agonists have to be given to allow ovulation to occur and then are usually stopped once pregnancy is diagnosed. In this fashion, the developing fetus has been exposed to the drug for about 4-6 weeks. There do not appear to be any risks

for fetal malformations or other adverse pregnancy outcomes with either bromocriptine or cabergoline. A recent review confirms no impairments in maternal–fetal outcomes in bromocriptine-induced pregnancies (6272 cases) as well as in cabergoline-induced pregnancies (1061 cases) regarding premature labor, abortions, and fetal malformations (47). Dopamine agonists are then reinstituted when breast-feeding is completed. In patients with expansive or invasive macroadenomas pregnancy can be recommended once the gonadotrophic axis is restored and only after tumor is reduced within the sellar boundaries. Otherwise, pituitary surgery is indicated (48). Symptomatic growth occurs in about 23% of macroprolactinomas and about 3% of microprolactinomas in the second or third trimester due both to the stimulatory effect of the high estrogen levels of pregnancy and the withdrawal of the dopamine agonist that may have been restraining tumor growth. Visual field testing should be carried out each trimester in patients with macroadenomas but in those with microadenomas only when they develop visual symptoms or progressive headaches. MRI scans (without gadolinium) are done in those patients who develop visual field defects or severe headaches when a therapeutic intervention is contemplated. Prolactin levels may rise during pregnancy when there is no tumor size change and some tumors enlarge without an associated rise in prolactin; therefore, measurement of prolactin during

pregnancy need not be carried out. When there is evidence of significant symptoms and tumor growth, the patient should be restarted on a dopamine agonist (49). Again, there are fewer data with cabergoline than bromocriptine but there is no particular reason to favor one versus the other in this context. Transsphenoidal surgical decompression can be performed if there is an unsatisfactory response to the dopamine agonist. Delivery of the baby and placenta can also be initiated if the pregnancy is sufficiently advanced.

## GUIDELINES

Shlomo Melmed, Felipe F. Casanueva, Andrew R. Hoffman, David L. Kleinberg, Victor M. Montori, Janet A. Schlechte, John A. H. Wass. Diagnosis and Treatment of Hyperprolactinemia: An Endocrine Society Clinical Practice Guideline. *The Journal of Clinical Endocrinology & Metabolism*, 2011;96(2): 273–288

Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD, Brue T, Cappabianca P, Colao A, Fahlbusch R, Fideleff H, Hadani M, Kelly P, Kleinberg D, Laws E, Marek J, Scanlon M, Sobrinho LG, Wass JA, Giustina A. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. *Clin Endocrinol (Oxf)*. 2006;65(2):265-273.

## REFERENCES

1. Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD, Brue T, Cappabianca P, Colao A, Fahlbusch R, Fideleff H, Hadani M, Kelly P, Kleinberg D, Laws E, Marek J, Scanlon M, Sobrinho LG, Wass JA, Giustina A. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. *Clin Endocrinol (Oxf)*. 2006;65(2):265-273.
2. Sonigo C, Bouilly J, Carre N, Tolle V, Caraty A, Tello J, Simony-Conesa FJ, Millar R, Young J, Binart N. Hyperprolactinemia-induced ovarian acyclicity is reversed by kisspeptin administration. *J Clin Invest*. 2012;122(10):3791-3795.
3. Gillam MP, Molitch ME, Lombardi G, Colao A. Advances in the treatment of prolactinomas. *Endocr Rev*. 2006;27(5):485-534.
4. Subasinghe CJ, Somasundaram N, Sivatharshya P, Ranasinghe LD, Korbonits M. Giant Prolactinoma of Young Onset: A Clue to Diagnosis of MEN-1 Syndrome. *Case reports in endocrinology*. 2018;2018:2875074.
5. Iacovazzo D, Hernandez-Ramirez LC, Korbonits M. Sporadic pituitary adenomas: the role of germline mutations and recommendations for genetic screening. *Expert Rev Endocrinol Metab*. 2017;12(2):143-153.
6. Srirangam Nadhamuni V, Korbonits M. Novel Insights into Pituitary Tumorigenesis: Genetic and Epigenetic Mechanisms. *Endocr Rev*. 2020;41(6).



7. Li C, Xie W, Rosenblum JS, Zhou J, Guo J, Miao Y, Shen Y, Wang H, Gong L, Li M, Zhao S, Cheng S, Zhu H, Jiang T, Ling S, Wang F, Zhang H, Zhang M, Qu Y, Zhang Q, Li G, Wang J, Ma J, Zhuang Z, Zhang Y. Somatic SF3B1 hotspot mutation in prolactinomas. *Nat Commun*. 2020;11(1):2506.
8. Soto-Pedre E, Newey PJ, Bevan JS, Greig N, Leese GP. The epidemiology of hyperprolactinaemia over 20 years in the Tayside region of Scotland: the Prolactin Epidemiology, Audit and Research Study (PROLEARS). *Clin Endocrinol (Oxf)*. 2017;86(1):60-67.
9. Newey PJ, Gorvin CM, Cleland SJ, Willberg CB, Bridge M, Azharuddin M, Drummond RS, van der Merwe PA, Klenerman P, Bountra C, Thakker RV. Mutant prolactin receptor and familial hyperprolactinemia. *N Engl J Med*. 2013;369(21):2012-2020.
10. Chen JX, Su YA, Bian QT, Wei LH, Zhang RZ, Liu YH, Correll C, Soares JC, Yang FD, Wang SL, Zhang XY. Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: A randomized, double-blind, placebo-controlled, dose-response study. *Psychoneuroendocrinology*. 2015;58:130-140.
11. Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, Wass JA, Endocrine S. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab*. 2011;96(2):273-288.
12. Vilar L, Abucham J, Albuquerque JL, Araujo LA, Azevedo MF, Boguszewski CL, Casulari LA, Cunha Neto MBC, Czepielewski MA, Duarte FHG, Faria MDS, Gadelha MR, Garmes HM, Glezer A, Gurgel MH, Jallad RS, Martins M, Miranda PAC, Montenegro RM, Musolino NRC, Naves LA, Ribeiro-Oliveira Junior A, Silva CMS, Viacelli C, Bronstein MD. Controversial issues in the management of hyperprolactinemia and prolactinomas - An overview by the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism. *Archives of endocrinology and metabolism*. 2018;62(2):236-263.
13. Kleinberg DL, Noel GL, Frantz AG. Galactorrhea: a study of 235 cases, including 48 with pituitary tumors. *N Engl J Med*. 1977;296(11):589-600.
14. Glezer AB, M. Hyperprolactinemia. In: De Groot LJC, G.; Dungan, K. , ed. [www.endotext.org](http://www.endotext.org). South Dartmouth: MDtext.com; 2000-2018.
15. Molitch ME. Medical management of prolactin-secreting pituitary adenomas. *Pituitary*. 2002;5(2):55-65.
16. Verhelst J, Abs R, Maiter D, van den Bruel A, Vandeweghe M, Velkeniers B, Mockel J, Lamberigts G, Petrossians P, Coremans P, Mahler C, Stevenaert A, Verlooy J, Raftopoulos C, Beckers A. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. *J Clin Endocrinol Metab*. 1999;84(7):2518-2522.
17. Sala E, Bellaviti Buttoni P, Malchiodi E, Verrua E, Carosi G, Profka E, Rodari G, Filopanti M, Ferrante E, Spada A, Mantovani G. Recurrence of hyperprolactinemia following dopamine agonist withdrawal and possible predictive factors of recurrence in prolactinomas. *J Endocrinol Invest*. 2016;39(12):1377-1382.
18. Cesak T, Poczos P, Adamkov J, Nahlovsky J, Kasparova P, Gabalec F, Celakovsky P, Choutka O. Medically induced CSF rhinorrhea following treatment of macroprolactinoma: case series and literature review. *Pituitary*. 2018.
19. Mantur M, Lukaszewicz-Zajac M, Mroczko B, Kulakowska A, Ganslandt O, Kemona H, Szmitkowski M, Drozdowski W, Zimmermann R, Kornhuber J, Lewczuk P. Cerebrospinal fluid leakage--reliable diagnostic methods. *Clin Chim Acta*. 2011;412(11-12):837-840.
20. Psaltis AJ, Schlosser RJ, Banks CA, Yawn J, Soler ZM. A systematic review of the endoscopic repair of cerebrospinal fluid leaks. *Otolaryngol Head Neck Surg*. 2012;147(2):196-203.
21. de Lacy P, Benjamin S, Dixon R, Stephens JW, Redfern R, Price DE. Is surgical intervention frequently required for medically managed macroprolactinomas? A study of spontaneous cerebrospinal fluid rhinorrhea. *Surg Neurol*. 2009;72(5):461-463; discussion 463.
22. Balarini Lima GA, Machado Ede O, Dos Santos Silva CM, Filho PN, Gadelha MR. Pituitary apoplexy during treatment of cystic macroprolactinomas with cabergoline. *Pituitary*. 2008;11(3):287-292.
23. Chng E, Dalan R. Pituitary apoplexy associated with cabergoline therapy. *J Clin Neurosci*. 2013;20(12):1637-1643.
24. Carija R, Vucina D. Frequency of pituitary tumor apoplexy during treatment of prolactinomas with dopamine agonists: a systematic review. *CNS Neurol Disord Drug Targets*. 2012;11(8):1012-1014.
25. Briet C, Salenave S, Bonneville JF, Laws ER, Chanson P. Pituitary Apoplexy. *Endocr Rev*. 2015;36(6):622-645.
26. Grand'Maison S, Weber F, Bedard MJ, Mahone M, Godbout A. Pituitary apoplexy in pregnancy: A case series and literature review. *Obstet Med*. 2015;8(4):177-183.
27. Davie M. Pathological gambling associated with cabergoline therapy in a patient with a pituitary prolactinoma. *J Neuropsychiatry Clin Neurosci*. 2007;19(4):473-474.
28. Bancos I, Nannenga MR, Bostwick JM, Silber MH, Erickson D, Nippoldt TB. Impulse control disorders in patients with dopamine agonist-treated prolactinomas and nonfunctioning pituitary adenomas: a case-control study. *Clin Endocrinol (Oxf)*. 2014;80(6):863-868.
29. Noronha S, Stokes V, Karavitaki N, Grossman AB. Treating prolactinomas with dopamine agonists: always worth the gamble? *Endocrine*. 2016;51(2):205-210.
30. Ahlskog JE. Pathological behaviors provoked by dopamine agonist therapy of Parkinson's disease. *Physiol Behav*. 2011;104(1):168-172.
31. Bulwer C, Conn R, Shankar A, Ferrau F, Kapur S, Ederies A, Korbonits M, Spoudeas HA. Cabergoline-related

---

impulse control disorder in an adolescent with a giant prolactinoma. *Clin Endocrinol (Oxf)*. 2017;86(6):862-864.

32. Ono M, Miki N, Kawamata T, Makino R, Amano K, Seki T, Kubo O, Hori T, Takano K. Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients. *J Clin Endocrinol Metab*. 2008;93(12):4721-4727.

33. Burlacu MC, Maiter D, Duprez T, Delgrange E. T2-weighted magnetic resonance imaging characterization of prolactinomas and association with their response to dopamine agonists. *Endocrine*. 2019;63(2):323-331.

34. Dogansen SC, Yalin GY, Tanrikulu S, Tekin S, Nizam N, Bilgic B, Sencer S, Yarman S. Clinicopathological significance of baseline T2-weighted signal intensity in functional pituitary adenomas. *Pituitary*. 2018;21(4):347-354.

35. Molitch ME. Management of medically refractory prolactinoma. *J Neurooncol*. 2014;117(3):421-428.

36. Drake WM, Stiles CE, Bevan JS, Karavitaki N, Trainer PJ, Rees DA, Richardson TI, Baldeweg SE, Stojanovic N, Murray RD, Toogood AA, Martin NM, Vaidya B, Han TS, Steeds RP, group UKCvs, Baldeweg FC, Sheikh UE, Kyriakakis N, Parasuraman SK, Taylor L, Butt N, Anyiam S. A Follow-Up Study of the Prevalence of Valvular Heart Abnormalities in Hyperprolactinemic Patients Treated With Cabergoline. *J Clin Endocrinol Metab*. 2016;101(11):4189-4194.

37. Stiles CE, Tetteh-Wayoe ET, Bestwick J, Steeds RP, Drake WM. A meta-analysis of the prevalence of cardiac valvulopathy in hyperprolactinemic patients treated with Cabergoline. *J Clin Endocrinol Metab*. 2018.

38. Colao A, Galderisi M, Di Sarno A, Pardo M, Gaccione M, D'Andrea M, Guerra E, Pivonello R, Lerro G, Lombardi G. Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. *J Clin Endocrinol Metab*. 2008;93(10):3777-3784.

39. Budayr A, Tan TC, Lo JC, Zaroff JG, Tabada GH, Yang J, Go AS. Cardiac valvular abnormalities associated with use and cumulative exposure of cabergoline for hyperprolactinemia: the CATCH study. *BMC Endocr Disord*. 2020;20(1):25.

40. MHRA. Secondary Ergot-derived dopamine agonists: risk of fibrotic reactions - GOV.UK 2008. 2008.

41. Caputo C, Prior D, Inder WJ. The need for annual echocardiography to detect cabergoline-associated valvulopathy in patients with prolactinoma: a systematic review and additional clinical data. *Lancet Diabetes Endocrinol*. 2015;3(11):906-913.

42. Colao A. Pituitary tumours: the prolactinoma. *Best Pract Res Clin Endocrinol Metab*. 2009;23(5):575-596.

43. Chen C, Yin S, Zhang S, Wang M, Hu Y, Zhou P, Jiang S. Treatment of aggressive prolactinoma with temozolomide: A case report and review of literature up to date. *Medicine (Baltimore)*. 2017;96(47):e8733.

44. Vilar L, Freitas MC, Naves LA, Casulari LA, Azevedo M, Montenegro R, Jr., Barros AI, Faria M, Nascimento GC, Lima JG, Nobrega LH, Cruz TP, Mota A, Ramos A, Violante A, Lamounier Filho A, Gadelha MR, Czepielewski MA, Glezer A, Bronstein MD. Diagnosis and management of hyperprolactinemia: results of a Brazilian multicenter study with 1234 patients. *J Endocrinol Invest*. 2008;31(5):436-444.

45. Colao A, Di Sarno A, Landi ML, Scavuzzo F, Cappabianca P, Pivonello R, Volpe R, Di Salle F, Cirillo S, Annunziato L, Lombardi G. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. *J Clin Endocrinol Metab*. 2000;85(6):2247-2252.

46. Berinder K, Stackenas I, Akre O, Hirschberg AL, Hulting AL. Hyperprolactinaemia in 271 women: up to three decades of clinical follow-up. *Clin Endocrinol (Oxf)*. 2005;63(4):450-455.

47. Huang W, Molitch ME. Pituitary Tumors in Pregnancy. *Endocrinol Metab Clin North Am*. 2019;48(3):569-581.

48. Glezer A, Bronstein MD. Prolactinomas in pregnancy: considerations before conception and during pregnancy. *Pituitary*. 2020;23(1):65-69.

49. Molitch ME. Prolactinoma in pregnancy. *Best Pract Res Clin Endocrinol Metab*. 2011;25(6):885-896.